Côd QR

Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?

Objective. Interstitial lung disease (ILD) is rare, but it is one of the most frequent extra-articular manifestations and a relevant cause of morbidity and mortality in rheumatoid arthritis (RA). Over the past few years, Janus kinase inhibitors (JAKis) have been reported to have promising efficacy...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: PAGEPress Publications 2025-01-01
Cyfres:Reumatismo
Pynciau:
JAK inhibitors
interstitial lung disease
ILD
rheumatoid arthritis
RA
Mynediad Ar-lein:https://www.reumatismo.org/reuma/article/view/1754
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg